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Introduction: Adipose-derived stroma cells (ASCs) are attractive cells for cell-based gene therapy but are generally
difficult to transfect. Nucleofection has proven to be an efficient method for transfection of primary cells. Therefore,
we used this technique to transfect ASCs with a vector encoding for Ambystoma mexicanum epidermal lipoxygenase
(AmbLOXe) which is a promising bioactive enzyme in regenerative processes. Thereby, we thought to even further
increase the large regenerative potential of the ASCs.
Methods: ASCs were isolated from the inguinal fat pad of Lewis rats and were subsequently transfected in passage 1
using Nucleofector® 2b and the hMSC Nucleofector kit. Transfection efficiency was determined measuring
co-transfected green fluorescent protein (GFP) in a flow cytometer and gene expression in transfected cells was
detected by reverse transcription polymerase chain reaction (RT-PCR). Moreover, cell migration was assessed using a
scratch assay and results were tested for statistical significance with ANOVA followed by Bonferroni’s post hoc test.
Results: High initial transfection rates were achieved with an average of 79.8 ± 2.82% of GFP positive cells although
longer cultivation periods reduced the number of positive cells to below 5% after four passages. Although successful
production of AmbLOXe transcript could be proven the gene product had no measureable effect on cell migration.
Conclusions: Our study demonstrates the feasibility of ASCs to serve as a vehicle of AmbLOXe transport for gene
therapeutic purposes in regenerative medicine. One potential field of applications could be peripheral nerve injuries.Introduction
The limitations of human nerve regeneration often lead
to unsatisfying results and impose special demands on
reconstructive surgery. While smaller lesions might result
in sufficient nerve regeneration, larger gaps practically
cannot be bridged by the regrowing proximal nerve
stump. Nerve regeneration depends on the structural
and biochemical composition of the existing micro-
environment and time is an important factor to maximize
the positive outcome. Even when impairing factors are
missing, supplementation of additional stimuli including
substructural elements and messenger molecules such as
growth factors enhance and direct axonal outgrowth [1].
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unless otherwise stated.to functionalize and optimize the microenvironment of
the nerve growth cone [2,3]. Gene therapy is mainly
intended to enhance the velocity of axonal regeneration,
which is important with regard to the increasing degeneration
of the distal nerve stump and the resulting continuing
loss of motor neurons [3]. Accordingly, most bioactive
molecules that have been delivered to experimental
models of denervated nerve stumps and injured spinal
and facial motor neurons by gene transduction are
neurotrophic proteins, although cell adhesion molecules
are also feasible [3].
The Mexican axolotl (Ambystoma mexicanum) is an
outstanding example of regenerative capacity and has
the ability for regeneration of functional body structures
like whole limbs as well as scar-free wound healing [4,5].
The axolotl’s regenerative abilities also include severe in-
juries to the peripheral nerve system and the spinal cord
[6,7]. As there is constant interest to develop strategiesLtd. This is an Open Access article distributed under the terms of the Creative
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mals, we intended to identify factors that promote healing
processes in the axolotl. In our previous study, we
described the identification of an enzyme expressed in
regenerating axolotl limbs which belongs to the epidermis-
type of lipoxygenases (A. mexicanum epidermal lipoxy-
genase (AmbLOXe)) [8]. The lipoxygenases belong to the
family of dioxygenases catalyzing the hydroperoxidation
of polyunsaturated fatty acids using linolic acid and
arachidonic acid as natural substrates. Lipoxygenase-
initiated mediator pathways activate proinflammatory
and anti-inflammatory signals alike [9], enabling a
tight regulation of innate immunity and inflammation.
AmbLOXe-expressing human cell populations showed
increased rates of cell migration in vitro [8].
In this study we hypothesized that adipose-derived
stroma cells (ASCs) can be nucleofected with a vector
encoding for AmbLOXe to use them for cell-based gene
therapy. A protocol for efficient transient transfection of
ASCs was developed and used for the production of
AmbLOXe-expressing cell populations. To test their
biological efficiency, the generated ASC populations
were kept in co-cultures with primary neurons.
Materials and methods
Adipose-derived stroma cell isolation and culture
ASCs were isolated using inguinal fat depots of adult
male Lewis rats weighing 350 to 400 g. The animals were
kept under standard conditions and written consent was
obtained by the Animal Welfare Commissioner of the
Hannover Medical School.
About 10 ml fat tissue was prepared from two anes-
thetized rats and the animals were sacrificed afterwards.
The tissue was minced and digested under shaking by
collagenase type I (CLS I, 2 mg/ml; Biochrom, Berlin,
Germany) at 37°C for 60 minutes. The cell suspension
was centrifuged at 175 × g for 5 minutes immediately
after the digestion and after a washing step with Hank’s
balanced salt solution (PAA, Pasching, Austria) +0.5%
bovine serum albumin (Sigma-Aldrich, St. Louis, MO,
USA). The resulting cell pellet was seeded in two 150 cm2
cell culture flasks (Biochrom) using Dulbecco’s modified
Eagle’s medium/F12 medium (Biochrom) with 100 U/ml
penicillin, 100 mg/ml streptomycin (PAA), 0.2 mM L-
ascorbic acid-2-phosphate (A2P; Sigma), and 10% fetal
bovine serum (Biochrom) and kept under standard cell
culture conditions.
The cells were characterized following the suggestions
of the International Society for Cellular Therapy [10]. In
brief, the expression of surface markers on freshly iso-
lated ASCs, passaged ASCs and nucleofected ASCs was
determined by flow cytometry using CD11b/c PerCP-
eFluor® 710 (eBioscience, Frankfurt, Germany), CD44H-
FITC (BD Bioscience, Heidelberg, Germany), CD45-FITC(Biolegend, Fell, Germany), CD90-PE/CY7 (Biolegend),
CD34 (Santa Cruz, Heidelberg, Germany), and CD73
(BD Pharmingen™, Heidelberg, Germany). When nee-
ded, unconjugated primary antibodies were incubated
with 1:10 diluted fluorochrome-labeled bovine anti-goat
IgG-PerCP-Cy5.5 (Santa Cruz) or goat-anti-mouse-IgG-
PE (Santa Cruz) as secondary antibodies. The labeled cells
were analyzed by a FC500 flow cytometer (Beckman
Coulter, Krefeld, Germany). Those measurements were
done either immediately after the isolation, for selected
samples after each passage or 7 days after the nucleofec-
tion process.
To survey the multipotency of the isolated cells they
were kept under inducing conditions as described in the
literature [11]. The cells were analyzed with the respect-
ive histological staining after the appropriate time.
Nucleofection of adipose-derived stroma cells
AmbLOXe [GenBank:EU814616.1] derived from AmbLOXe
pSTBlue-1plasmid [8] was subcloned into a unique EcoRI
restriction site of the pIRES–EGFP vector (Clontech,
Mountain View, CA, USA). The resulting plasmids were
purified using the EndoFree Plasmid Maxi Kit (Qiagen,
Hamburg, Germany). The fidelity and orientation of
pIRES-EGFP-AmbLOXe (pI-AmbLOXe) was confirmed
by restriction digest and sequencing at a local sequencing
service (GATC, Stuttgart, Germany).
Cultures of ASCs were nucleofected at passage 1 with
either pI-AmbLOXe, pIRES-EGFP (empty vector con-
trol), and/or the control vector pmaxGFP® (Lonza, Basel,
Switzerland) using the Human MSC Nucleofector kit
(Lonza) according to the manufacturer’s instructions. Ne-
gative controls were transfected without adding vector
DNA. In brief, 105 cells were resuspended in 100 μl
Nucleofector solution, mixed with 3 μg plasmid DNA,
transferred to a cuvette and nucleofected using program
A-033 of the nucleofector device. Control cells were
treated analogously, but without DNA addition. Nucleo-
fected samples were transferred to 500 μl prewarmed
medium and seeded in six-well plates at a density of 105
cells per well. Cells were incubated 3 days under standard
conditions before being analyzed. The nucleofection effi-
ciency was determined by detection of green fluorescent
protein (GFP)-positive cells in a flow cytometer (FC-500;
Beckman Coulter). To analyze the stability of nucleofec-
tion, the percentage of GFP-positive cells was measured
on days 3, 6, and 12 after cell passage. Cells were sub-
cultured four times at a ratio of 1:1, with 3 days between
each plating.
Comparison of transfection methods
Different transfection reagents were tested for their
efficiency following the protocols provided by the ma-
nufacturers: FugeneHD (Promega, Madison, WI, USA),
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tremeGene-HP (Roche).
Gene expression analysis
To confirm AmbLOXe expression in transfected ASCs,
500 ng total RNA were isolated by NucleoSpin® RNA II
kit (Macherey-Nagel, Düren, Germany) and reverse tran-
scribed using the iScript cDNA Synthesis Kit (BioRad,
Munich, Germany) according to the manufacturer’s
instructions. Polymerase chain reactions were performed
with AmbLOXe-forward primer 5′-ATGGTGGATGAG
TACCGCATCAAAGA-3′ and AmbLOXe reverse primer
5′-TATGGACACACTGTTCTCTATCACTT-3′ using
Advantage® 2 Polymerase Mix (Clontech/Takara, Mountain
View, CA, USA), Advantage™ 2SA buffer (Clontech/
Takara), 2.5 μM nucleotide mixture (Clontech/Takara),
and 2 μl produced cDNA on a Mastercycler Personal
(Eppendorf, Hamburg, Germany). As a positive control,
0.5 μl AmbLOXe-pIRES vector was run in parallel. The
amplification products were analyzed on a 1% (w/v)
agarose gel supplemented with ethidium bromide and
documented by the Biovision system (Vilber Lourmat,
Eberhardzell, Germany).
Cytotoxicity and cell metabolism
Cytotoxicity testing was done with CytoTox One (Promega)
and determination of the cell metabolic activity with
CellTiter-Blue (Promega).
Cells (103) in 200 μl standard cell culture medium
were seeded into 96-well plates in hexaplicate 30 mi-
nutes after nucleofection. The cells were incubated for
24 or 72 hours under standard cell culture conditions.
Living ASCs without nucleofection and cells lysed in the
lysis buffer included in the kit were used as the respect-
ive controls. Medium without cells was measured for
determination of the background.
For the cytotoxicity assay, 100 μl cell culture super-
natant were transferred to a new 96-well plate to pro-
ceed as stated by the manufacturer. For determination of
the metabolic cell activity, substrate was directly added
to the cultures and incubated at 37°C for 3 hours,
following the instructions of the manufacturer.
Fluorescence was measured at excitation 560 nm/emission
590 nm on a filter-equipped plate reader (Genios, Tecan,
Grödig, Austria). The measurements were repeated at two
independent times. Means and standard deviations were
calculated and tested for statistical significance with
analysis of variance followed by Bonferroni’s post hoc test.
Scratch assay
To analyze the cell migration, scratch tests were per-
formed for ASC populations that either were left with-
out nucleofection or were nucleofected without DNA
or with pI-AmbLOXe, pmaxGFP® or a mixture of both(1:2), respectively. The day after nucleofection, cells were
seeded in triplicate into 12-well plates at 105 cells per
well and cultured under standard conditions (Dulbecco’s
modified Eagle’s medium/F12 with 100 U/ml penicillin,
100 mg/ml streptomycin, 0.2 mM L-ascorbic acid-2-
phosphate, and 10% fetal bovine serum, humidified at-
mosphere, 37°C, 5% carbon dioxide) for 2 days, in which
time they reached confluence. The monolayers were then
wounded with a disposable plastic pipette tip (10 to 100 μl
volume) to create the scratch, rinsed with phosphate-
buffered saline (Gibco, Grand Island, NY, USA), and incu-
bated in ASC medium. The scratches were documented
microphotographically every 6 hours over 36 hours. Clos-
ing of scratches was analyzed using the image analysis
software Cell-D (Olympus, Hamburg, Germany). The
scratch length and cell-free area were measured and
the mean distances between cell fronts were calculated.
Scratch tests were carried out in four independent expe-
riments. Means and standard deviations were calculated
and tested for statistical significance with analysis of
variance followed by Bonferroni’s post hoc test.
Isolation of neurons from dorsal root ganglia
Dorsal root ganglia were excised from adult rats previ-
ously sacrificed under anesthesia in ice-cold conditions.
The collected ganglia were prepared and digested with
1.7 mg/ml collagenase A (Roche), 1.7 mg/ml collagenase
D (Roche), and 1.25 mM calcium chloride (Sigma).
An additional treatment with 2.5 mg/ml papain (Sigma),
100 mM L-cystein (Sigma) and 10 mM ethylenediamine
tetraacetic acid (Sigma) was performed at 37°C for 5
minutes. After mechanical dissociation the neurons were
kept in a modified Bottenstein and Sato medium con-
sisting of Dulbecco’s modified Eagle’s medium/F12 + 6%
D-glucose (Sigma) supplemented with 100 μg/ml bovine
serum albumin, 100 μg/ml transferring (Sigma), 100 μM
putrescine (Sigma), 30 nM sodium selenite (Sigma),
20 nM progesterone (Sigma), 10 nM insulin (Sigma),
and 1% of 100 U/ml penicillin, 100 mg/ml strepto-
mycin and were plated onto laminin-coated (Sigma)
cell culture vessels.
For co-culture experiments, the transfected ASCs were
mixed with a freshly prepared suspension of dorsal root
ganglia neurons and plated in triplicate at a density of
10,000 ASCs and 1,000 neurons on cover glasses. After
24 hours and 48 hours, respectively, the samples were
fixed in 4% (w/v) paraformaldehyde (Karlsruhe, Germany)
in phosphate-buffered saline and analyzed by digital
microphotography using the CKX41 imaging system
(Olympus) and image analysis software imageJ (National
Institutes of Health, Bethesda, MD, USA). The numbers
and lengths of the outgrowing neurites were measured in
five independent experiments. The results are presen-
ted as means and standard deviations and were tested
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of variance followed by Bonferroni-corrected Mann–
Whitney U test.
Results
Nucleofection of adipose-derived stroma cells
AmbLOXe, an effector of amphibian regeneration, was
shown to induce increased in vitro wound closure rates
in some mammalian cell lines that were transfected with
it [8]. Aiming at an improvement in tissue regeneration,
AmbLOXe included in pIRES-EGFP vector (pl-AmbLOXe)
was nucleofected into rat ASCs.
Our pre-examinations to select a suitable transfection
technique revealed that the mean transfection efficien-
cies were very low with common transfection reagents,
such as FugeneHD (0.21 to 2.2%), X-tremeGene 9 (0.0 to
0.05%), and X-tremeGene-HP (0.06 to 0.3%), with slight
variances depending on the relation between DNA and
reagent.Figure 1 Nucleofection of adipose-derived stroma cells. For the establ
green fluorescent protein (GFP) was used and detected with a fluorescent
percentages of GFP-positive cells. The transfection rates were determined t
numbers of positive cells over time and passage. (B) First three columns repre
(subculture No. 0); following columns are grouped as passages 1 to 4 after nu
directly under the columns indicate the days after nucleofection or passagingIn contrast, ASCs could successfully be transfected by
nucleofection. The efficiency of this technique was de-
termined by the control vector pmaxGFP®, resulting in
bright green fluorescence after vector uptake (Figure 1A).
The percentages of positive cells were analyzed by subse-
quent flow cytometry. The mean transfection efficiency
obtained at day 3 after nucleofection (maximum of ex-
pression) was 79.8 ± 2.82% (n =11). The nucleofection
was highly reproducible but transient; 12 days after the
gene transfer, only 36.05 ± 6.29% of cells expressed GFP.
When the nucleofected cells were subcultured, the aver-
age percentage of GFP-positive cells was 3.03 ± 2.4%
after four passages (Figure 1B).
Detection of AmbLOXe expression
AmbLOXe expression was detected by polymerase chain
reaction amplification of cDNA reverse transcribed from
RNA isolated from nucleofected cell populations. The
nucleofection with pI-AmbLOXe was compared withishment of a transfection protocol, the vector pmaxGFP® encoding for
microscope (A) or a flow cytometer (B). Data are presented as
o be 79.8 ± 2.82% on average at the beginning but showed reducing
sent the original culture after the nucleofection without subculturing
cleofection as indicated below (subculture No. 1 to 4). The numbers
, respectively.
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pI-AmbLOXe/pmaxGFP®, as well as a control nucleo-
fection without DNA (Figure 2). As a positive control,
the same polymerase chain reaction was performed with
diluted vector encoding AmbLOXe.
In samples nucleofected with pI-AmbLOXe and in the
positive control, a band around 1,800 base pairs – which
corresponds to the size of full-length AmbLOXe – could
be detected (Figure 2, lanes 4 to 6). No bands were ob-
served after nucleofection without DNA or with pmaxGFP®
(Figure 2, lanes 2 and 3, respectively).Lactate dehydrogenase release and cell metabolic activity
To rule out any harmful effect of nucleofection and/or
AmbLOXe expression, we measured lactate dehydrogen-
ase (LDH) release and resazurin to resorufin reduction
by cell metabolism (Figure 3). On day 1 after nucleofec-
tion, all samples that underwent the procedure showed
reduced cell metabolism compared with the untreated
cells (Figure 3A). On day 3 most cell populations recov-
ered from the process, with exception of the double-
transfected cells (pApmax) (Figure 3B). The first day
after handling the cells, LDH release was measurable in all
cell populations, especially those expressing AmbLOXe
(Figure 3C), but on day 3 all cell populations recov-
ered and only trace amounts of LDH could be detected
(Figure 3D).Figure 2 Expression of AmbLOXe in the nucleofected adipose-
derived stroma cells. Ambystoma mexicanum epidermal
lipoxygenase (AmbLOXe) expression was detected by polymerase
chain reaction in the nucleofected cell populations 5 days after
transfection. In pIRES-EGFP-AmbLOXe (pI-AmbLOXe) nucleofected
cells, pI-AmbLOXe/pmaxGFP® co-nucleofected cells (ratio 1:1) as well
as in the positive control (pI-AmbLOXe vector), a band corresponding
to the size of full-length AmbLOXe could be detected (lanes 4 to 6).
No bands were observed after nucleofection without DNA or with
pmaxGFP® alone (lanes 2 and 3). Lane 1, DNA ladder; lane 2,
nucleofection without DNA; lane 3, nucleofection with pmaxGFP®;
lane 4, nucleofection with pI-AmbLOXe; lane 5, nucleofection
with pI-AmbLOXe/pmaxGFP®; lane 6, pI-AmbLOXe alone as vector
(positive control); lane 7, water (negative control).Influence of AmbLOXe expression on the ASC phenotype
The cell surface markers of mesenchymal stem cells
(MSCs) as assigned by Dominici and colleagues were
determined before and 7 days after nucleofection [10].
No significant difference was observed in cell popula-
tions that were transfected with a vector encoding for
AmbLOXe or with empty vectors, and in cells transfected
without adding DNA or left completely untreated (data
not shown).
To determine whether AmbLOXe expression had a
measurable influence on ASC migration velocity, conflu-
ent monolayers of ASCs nucleofected without DNA, with
pI-AmbLOXe, with a GFP-expressing vector (pmaxGFP®)
or with a mixture of both (50% pI-AmbLOXe and 50%
pmaxGFP®), were scratched and their closing analyzed. In
all groups, scratches were closed after 30 hours. Untreated
ASCs were used as controls. There was a uniform
decrease of mean distance, and no significant difference
between the groups could be found over time (Figure 4).
Influence on number and length of outgrowing neurites
in co-culture experiments
To test whether ASCs could be used for cell-based gene
therapy delivering ectopically expressed AmbLOXe, we
next performed co-culture experiments. Primary neu-
rons derived from rat dorsal root ganglions and ASC cell
populations transfected with either a vector encoding for
AmbLOXe or with the same vector without coding se-
quence were kept together for 24 or 48 hours, respect-
ively. Counting the mean number of outgrowing neurites
revealed no difference between the samples, neither after
24 hours nor after 48 hours. Concerning the neurite
length, a slight difference could be detected. After 24
hours, the mean length of neurites was 41.3 ± 29.18 μm
when the neurons were kept in co-cultures with an
ASC population nucleofected with the empty vector and
was 53.27 ± 40.96 μm when the co-cultures contained
AmbLOXe-expressing ASCs. After 48 hours the mean
lengths were 155.63 ± 104.98 μm compared with 190.49 ±
143.87 μm (Figure 5). Although the differences were not
significant due to the high variances of neurite lengths,
there is a tendency for AmbLOXe expression in ASC
populations to enhance neurite outgrowth.
Discussion
Adult MSCs are a widely used cell type in regenerative
medicine. There are a number of studies indicating that
transplanted MSCs are attracted to sites of tumors/
metastases, injury, inflammation and ischemia [12]. In
the setting of stem cell transplantation, MSCs from
neonatal skin have been shown to be a potential therapy
for collagen VI-related congenital muscular dystrophy
by integration of the cells into the skeletal muscle and
production of the missing collagen VI in a mouse model
Figure 3 Measurement of lactate dehydrogenase release and cell metabolism. Cells were seeded into 96-well plates and incubated for the
indicated time points. The respective substrates were either added to the cells (cell metabolism) or to the cell culture supernatants (lactate
dehydrogenase (LDH)). After the appropriate time and conditions, fluorescence was measured and given in arbitrary units. (A), (B) Cell metabolism on
day 1 and day 3, respectively. (C), (D) LDH release on day 1 and day 3, respectively. Nontransfected cells (columns 5 and 6) were used as the respective
controls. Significant differences observed between the Ambystoma mexicanum epidermal lipoxygenase (AmbLOXe)-expressing cells and the other cell
populations are indicated (***P >0.001). Group 1, pIRES-EGFP-AmbLOXe (pI-AmbLOXe); Group 2, pmaxGFP®; Group 3, 50% pI-AmbLOXe and 50%
pmaxGFP®; Group 4, cells nucleofected without DNA; Group 5, untreated adipose-derived stroma cells (ASCs); Group 6, untreated ASCs in lysis buffer.
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for autoimmune encephalomyelitis and multiple sclerosis,
also in a mouse model [14]. A combination of stem cell
therapy and myocardial gene therapy in the peri-infarcted
region of rats improved cardiac function 4 weeks after
myocardial infarction [15]. ASCs can also be used forFigure 4 Scratch test of nucleofected adipose-derived stroma cells. Sc
(ASCs) nucleofected with pIRES-EGFP-AmbLOXe (pI-AmbLOXe), the empty
groups could be found over time. White column, cells nucleofected withou
arrowheads), 50% pI-AmbLOXe and 50% pmaxGFP®; grey column, pmaxGF
epidermal lipoxygenase.cell-based gene therapy by overexpressing the desired
therapeutic factors; for example, for enhancing angiogen-
esis [16]. ASCs have been defined as a subpopulation of
adipose tissue stroma cells with a multipotent differenti-
ation capability and are thus regarded as a special type of
MSCs [11]. ASCs are able to integrate into host tissue andratch tests in confluent monolayers of adipose-derived stroma cells
vector or a mixture of both. No significant differences between the
t DNA; striped column, pI-AmbLOXe; patterned column (small
P®; black column, untreated ASCs. AmbLOXe, Ambystoma mexicanum
Figure 5 Morphometric analysis of neurite numbers and lengths of neurons kept in co-cultures with adipose-derived stroma cells.
(A) Mean number of neurites in absolute numbers. (B) Mean length of neurites (μm). Time points of data analyses were after 24 hours and
48 hours, respectively. White column, co-cultures without AmbLOXe-expressing ASCs (pA(-)); grey column, co-cultures with AmbLOXe-expressing
ASCs (pA(+)). AmbLOXe, Ambystoma mexicanum epidermal lipoxygenase; ASC, adipose-derived stroma cell.
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ASCs are a convenient source of adult stem cells since
they can be isolated from lipoaspirates with minimal
invasive surgical intervention, they can be harvested in
sufficient amounts, and they are easy to propagate in cell
culture [11]. These observations emphasize the versatility
of MSCs/ASCs in different regenerative processes,
possibly combined with gene therapy.
Exploitation of MSCs/ASCs as vehicles for cell-based
therapies is feasible but is hampered by the relatively
weak transfectability of these primary cells [16]. We and
others tried transfection reagents with limited success;
for example, Aluigi and colleagues used nucleofection
successfully to transfect human MSCs, in contrast to
commercial transfection reagents such as Fugene and
DOTAP that transfected the cells at the low rate of
3.6 ± 2.4% and 5.4 ± 3.4% respectively [17]. The same
was observed in other studies where treatment of human
MSCs with various transfection reagents resulted in low
transfection rates or no transfection at all [18,19].
The use of viral vectors has been proposed [20] but
falls under safety concerns [21] and offers limited space
for foreign gene integration. Other methods used for
MSC/ASC transfection include chemical and physical
methods such as polyethyleneimine-mediated gene de-
livery [22], biodegradable polymeric vectors [23], or elec-
troporation [24]. In our study we used the nucleofection
method for transient transfection of rat ASCs at high
rates. Nucleofection is a method to deliver plasmid DNA
into cells based on an electroporation system equipped
with programs specific for different cell types. It is pos-
sible to vary the duration, frequency and voltage of the
electrical pulses in combination with cell type-specific
transfection buffers. This has been used successfully for
a number of cells difficult to transfect, among them
human bone marrow-derived MSCs [25]. Although theoriginal protocol was designed for human stem cell trans-
fection, we could adapt it to the isolated rat ASCs. When
tested with a GFP-encoding vector, transfection rates of
79.8 ± 2.82% could be achieved and AmbLOXe transcript
could be demonstrated in ASC populations transfected
with an AmbLOXe-encoding vector. Although the cells
were affected by the handling and the nucleofection, they
quickly recovered to normal cell metabolism and LDH
release rates on day 3.
To rule out any influence of AmbLOXe expression on
the ASCs, we detected MSC markers on the surface of
cell populations either expressing AmbLOXe or not. No
difference concerning these marker proteins’ expression
could be observed. We next performed scratch assays to
assess the migration velocity, which is a clear sign of
AmbLOXe activity [8], but no influence on the ASCs
respective to the controls could be observed. As no
obvious change in the ASC phenotype could be de-
tected, we conclude that ASCs can be used as vehicles
for the transport of AmbLOXe-encoding vectors without
themselves being affected.
The regenerative potential of both the ASCs as such
and the addition of AmbLOXe might be used in clinical
settings such as healing of damaged nerves. In the case
of peripheral nerve injury, an early stimulation of neurite
outgrowth is favorable and long cell extrusions with
minimal branches indicate directed outgrowth. This can
be achieved by genetic transfer of neurotrophic factors
such as nerve growth factor. The reaction of neurons to
such growth factors were shown to be dosage dependent
in a way that lower levels of transfection can be more ef-
fective than maximum levels [26]. In a first proof of
principle, AmbLOXe-expressing ASC populations were
able to stimulate neurite outgrowth in our direct co-
culture experiments. Although the results were not sig-
nificant, they were promising and require optimization.
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AmbLOXe-based gene therapy include the variation of
the vector system; for example, exchanging the viral
promoter with a strong cellular promoter. Also, the most
effective dose of AmbLOXE-expressing cells needs to be
determined. Therapeutic delivery of a lipoxygenase in a
therapeutic context is a new approach. In recent studies,
gene transfer of lipoxygenase 15-1 was used for inhib-
ition of angiogenesis in different setting [27,28]. We
expect that genetic transfer of AmbLOXe as an inducer
of cellular growth is an important option for future
therapeutic approaches, especially in the context of
nerve regeneration.
Conclusion
ASCs can successfully and efficiently be transfected by
nucleofection and thereby may serve as a vehicle for gene
therapy. Especially, transfection with AmbLOXe may be
valuable in the field of regenerative medicine; for example,
in the case of peripheral nerve injuries.
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